![Sample Title](/content/hub5/first-big-drugs-2024/_jcr_content/root/container/container/column_half_copy_cop/col1/o4_adaptiveimage.jpg)
Welcome to the first Drug Pipeline Insights Report for 2024
Read the report for a review of:
- First approved drug for negative symptoms of schizophrenia
- First-in-class treatment for pulmonary arterial hypertension
- First FDA-approved drug for nonalcoholic steatohepatitis (NASH).
Don't want to read the full report? View the summary.
Related content
![](/content/dam/o4-dam/images/professionals/pharmacies/pill-and-injection-1080x720.jpg)
Optum Rx Drug Pipeline Insights Reports
Read the most recent quarterly reports on new drugs coming down the pipeline.
![](/content/dam/o4-dam/images/professionals/pharmacies/two-women-tablet-1200x628.jpg)
3 ways to deal with escalating drug costs
Innovations custom built for today’s specialty challenges.
![](/content/dam/o4-dam/images/professionals/pharmacies/meeting-1080x720.jpg)
Transforming the pharmacy industry with transparency
Hear how the industry’s most transparent and independent Pharmacy & Therapeutics Committee evaluates drugs for the Optum Rx formulary.